Cargando…

THU287 Comparison Of Renal Protective Effects Between SGLT2 Inhibitors And DPP4 Inhibitors In Real-World Clinical Practice

Disclosure: H. Park: None. S. Park: None. S. Kwon: None. H. Kim: None. D. Byun: None. Recent prospective randomized studies have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors had renal protective effects compared to placebo. In this study, we compared the renal composite outcomes betw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Hyeong-Kyu, Park, Sang-Joon, Kwon, Soon-Hyo, Kim, Hye-Jung, Byun, Dong-Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Diabetes And Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553520/ http://dx.doi.org/10.1210/jendso/bvad114.723

Ejemplares similares

THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
por: Abrahimi, Nora, et al.
Publicado: (2023)

THU360 Hyperglycemic DKA In Patient On Monotherapy With SGLT-2 Inhibitor
por: Ahmed, Samihah, et al.
Publicado: (2023)

THU347 Diffusion Tensor Imaging Of The Tibial Nerve Can Detect Peripheral Neuropathy In Type 2 Diabetes
por: Park, Hyeong-Kyu, et al.
Publicado: (2023)

THU389 Euglycemic Diabetic Ketoacidosis With Prolonged Ketosis Due To SGLT-2 Inhibitor
por: Viera Feliciano, Natalia, et al.
Publicado: (2023)

THU247 Characterizing Inpatient Cases Of DKA Precipitated By SGLT2 Inhibitor Use
por: Aslamy, Arianne, et al.
Publicado: (2023)

THU291 Successful Reversal Of Glucose Toxicity After DKA Precipitated By SGLT2 Inhibitor
por: Abdelrahman, Houda, et al.
Publicado: (2023)

THU359 A Classical Case Of SGLT-2 Inhibitor Euglycemic Ketoacidosis In A Patient With Glucotoxicity
por: Amankwah, Samuel, et al.
Publicado: (2023)

THU345 SGLT2 Inhibitors Reduce Mortality In Patients With Acute Myocardial Infarction And Percutaneous Coronary Intervention: A Systematic Review And Meta-analysis
por: Goncalves Ribeiro, Sandro Augusto, et al.
Publicado: (2023)

THU380 A Case Of Alpelisib Induced Diabetic Ketoacidosis (Dka) In A Patient With Type 2 Diabetes Mellitus And Rechallenge With SGLT2 Inhibitor
por: Sekar, Vijaykumar, et al.
Publicado: (2023)

THU282 Improved Fournier’s Gangrene Outcomes With Prior SGLT2i Or Metformin Usage
por: Venugopal, Sharini, et al.
Publicado: (2023)

ODP242 Safety of SGLT2-Inhibitors in Patients with Multiple Myeloma and Diabetes
por: Shyu, Margaret, et al.
Publicado: (2022)

ODP244 SGLT2 Inhibitor-Induced Euglycemic DKA and its Challenges
por: Penna, Laurianne El Musa, et al.
Publicado: (2022)

THU353 Late Onset Of Immune Checkpoint Inhibitor-Related Diabetes After 3 Years
por: Avula, Sreekant, et al.
Publicado: (2023)

ODP173 Control of Alpelisib-Induced Hyperglycemia With DPP4- Inhibitors as add on to Metformin and Insulin
por: Hee, Nicholas Ken Yoong, et al.
Publicado: (2022)

PSUN190 Is Euglycemic Diabetic Ketoacidosis an Underrecognized Risk of SGLT2 Inhibitor Utilization?
por: Block, Romy, et al.
Publicado: (2022)

SAT087 Maternally Inherited Diabetes And Deafness: Support For SGLT2 Inhibitor Use
por: Pandya, Stuti, et al.
Publicado: (2023)

THU281 Real-World Survey Of Adherence To Guidelines Regarding Type 1 Diabetes And Aerobic Exercise
por: Anthony Henske, Joseph, et al.
Publicado: (2023)

THU298 Effect Of SGLT2 Inhibition On Metabolic, Cardiac And Renal Outcomes In Heart Transplant Recipients (EMPA-HTx study): Protocol And Study Design
por: Raven, Lisa M, et al.
Publicado: (2023)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

Euglycemic DKA Associated With SGLT2 Inhibitors
por: TakallooBakhtiari, Asieh, et al.
Publicado: (2021)

PSUN263 Diagnosis of Latent Autoimmune Diabetes of Adulthood Unveiled After Initiation of an SGLT2 Inhibitor
por: Patel, Goonja, et al.
Publicado: (2022)

LBODP041 Effects Of Sodium-glucose Co-transporter 2 Inhibitors (sglt-2 Inhibitors) On Adipokines And Inflammatory Biomarkers In Type2 Diabetic Patients
por: Kumtree, Phonphruet
Publicado: (2022)

ODP183 Diabetic Ketoacidosis Precipitated by Ketogenic Diet and SGLT-2 Inhibitor Use in an Individual with T2DM
por: Mason, Timothy, et al.
Publicado: (2022)

PSUN199 SGLT2-Inhibitor Prescription Rates in Individuals with Diabetic Nephropathy at a Teaching Outpatient Clinic
por: Abdulwahid, Tiba, et al.
Publicado: (2022)

THU338 Risks Of Stroke, Its Subtypes And Atrial Fibrillation Associated With Glucagon-like Peptide 1 Receptor Agonists Versus Sodium-glucose Cotransporter 2 Inhibitors: A Real-world Population-based Study In Hong Kong
por: Lui, David, et al.
Publicado: (2023)

THU342 Per And Polyfluoroalkyl Substances And Prevalence Of Diabetes Mellitus In Korean Adults
por: Kim, Shin-Hye
Publicado: (2023)

THU372 Finasteride Induced Hyperglycemia
por: Bose, Vivek, et al.
Publicado: (2023)

ODP604 | LBSUN287 Ketosis-prone Type 2 Diabetes (Flatbush Diabetes) In Remission: Report Of Two Cases
por: Ji, Beisi, et al.
Publicado: (2022)

PSUN172 Prescribing SGLT-2 Inhibitors and GLP-1 Agonists in Primary Care: Improving Rates of Guideline-Concordant Practice
por: Schuetz, Samantha, et al.
Publicado: (2022)

ODP212 Inpatient Euglycemic DKA due to SGLT2 Inhibitors – Lessons From a Case Series and Strategies to Decrease Incidence
por: Burkhardt, Daniel, et al.
Publicado: (2022)

THU295 The Role Of Imatinib In Pediatric Diabetes
por: Lavelle, Kristen, et al.
Publicado: (2023)

Euglycemic DKA in Patients on SGLT2 Inhibitor and Potentially Ketotic State
por: Khalifa, Maram, et al.
Publicado: (2021)

THU299 Safety Of Immune Checkpoint Inhibitor Cancer Therapy In Patients With Pre-existing Type 1 Diabetes Mellitus: A Multi-Center Cohort Study
por: Hilder, Robin, et al.
Publicado: (2023)

SUN-156 Exosomal MicroRNA Profile in Korean Obese Subjects with Prediabetes and Those with Type 2 Diabetes Mellitus
por: Park, Hyeong-Kyu, et al.
Publicado: (2019)

LBSUN289 Ketonuria — A Possible Early Indicator Of Impending Euglycemic DKA In Setting Of Recent SGLT-2 Inhibitor Use And Acute Stress
por: Arora, Gunjan, et al.
Publicado: (2022)

THU352 Troponin Elevation On The Outcomes Of Hospitalized Patients With Diabetic Ketoacidosis: Analysis Of National Inpatient Sample
por: Karki, Sadichhya, et al.
Publicado: (2023)

THU302 Protective Effects Of Lactation On Maternal Metabolism
por: Hens, Julie R, et al.
Publicado: (2023)

THU354 Enfortumab Vedotin Induced Refractory Hyperglycemia
por: Hussein, Marwah, et al.
Publicado: (2023)

Precipitation of Euglycemic DKA (euDKA) From the Initiation of SGLT2 Inhibitor (SGLT2i) and 0-Carb Diet Inpatient
por: Popli, Rakesh, et al.
Publicado: (2021)

PSUN196 Outcomes following SGLT-2 inhibitor use in 99 patients with type 1 diabetes: A single-centre, retrospective, chart-review study
por: William, Jovitta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1q2kjn39471upq9nvfd55eidmp